Advancing Alzheimer’s Disease Early Detection with Circular RNA
Detecting Alzheimer’s Early to Preserve What Matters Most
In the United States, about 1 in 9 people aged 65 and older has Alzheimer's disease, and as the population continues to age, its prevalence is rising at an unprecedented rate. Currently, 7 million Americans are living with AD, and this number is projected to reach nearly 13 million by 2050.
1
Diagnosis today often comes too late—after irreversible brain damage has already occurred. Although research and therapeutic developments are advancing toward earlier detection, a critical gap remains in how patients with cognitive concerns are identified and evaluated. Bridging this gap is essential, as early detection can help people access treatments, participate in clinical research, and proactively make lifestyle changes that delay symptom onset and disease progression.²
From biology to pathology:
A broader view of Alzheimer’s disease
Alzheimer’s disease is biologically complex and heterogenous, driven by multiple interconnected processes that evolve differently across individuals. As our understanding of the disease deepens, it’s becoming clear that upstream molecular dysregulation extends beyond traditional pathological changes — revealing new opportunities for more comprehensive approaches to detection and treatment.
91%
of human biological pathways are affected in Alzheimer's disease
When you look across all known cellular signaling and metabolic systems, genes and proteins are involved in nearly every biological process and show some change in Alzheimer's biology and pathology - confirming the disease is systemic and multifactorial.
3
Circular RNA: A Novel Class of Biomarkers for the Early Detection of Alzheimer’s Disease
Circular RNAs (circRNAs) are a novel class of non-coding RNA molecules that capture early biological changes associated with AD. CircRNAs have unique biological properties that position them as having high clinical utility in AD diagnosis and serve as potential targets in therapeutic discovery.
Our approach: Comprehensive detection of a complex disease
Our circRNA platform is designed to reflect a more comprehensive view of Alzheimer’s biology by capturing dysregulation across multiple interconnected pathways – including neuroinflammation, neuronal plasticity, synaptic dysfunction, oxidative stress, and amyloid/tau biology. By providing a broader biological view, it reduces diagnostic ambiguity, improves detection across the entire disease continuum, and aligns with the future of precision medicine and multi-target therapies.
CircRNAs enable a systems-level view of Alzheimer’s Disease
Join Us in Advancing Alzheimer’s Research
References:
1. https://www.alz.org/alzheimers-dementia/facts-figures
2. https://www.alz.org/us-pointer/home.asp
3. Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A. Developing the ATX(N) classification for use across theAlzheimer’s disease continuum. Nature Reviews Neurology. 2022 Jul;18(7):400–413. doi:10.1038/s41582-022-00693-9. PMID:35773214; PMCID: PMC9263183.